A Phase I Study of PHA-739358 in Adult Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant or Intolerant to Imatinib and/or other 2nd Generation c-ABL Therapy.

Trial Profile

A Phase I Study of PHA-739358 in Adult Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant or Intolerant to Imatinib and/or other 2nd Generation c-ABL Therapy.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2010

At a glance

  • Drugs Danusertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 21 Nov 2009 Planned number of patients changed from 60 to 50 as reported by M.D. Anderson Cancer Center.
    • 15 Apr 2009 Actual initiation date (3 Jun 2008) added as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top